Sep 12, 2019
UT Southwestern and Regulus Therapeutics Inc., a biopharmaceutical company based in California, are working on a new treatment for polycystic kidney disease. The new treatment showed no evidence of toxicity in animals or in human cell tests. It is preferentially delivered to kidneys rather than the liver after being administered.
In the animal study, the afflicted mice show an approximately 50 percent reduction in kidney following treatment.
Early phase one clinical trials began last year, conducted by Regulus Therapeutics.